Clinical trials: Advanced Malignancies, open to volunteers
Locally Advanced Cervical Carcinoma
HYpofractionated Pelvic Radiotherapy for Advanced Cervical Cancers INeligible for ChemoTherapy
BACKGROUND: For patients with locally advanced cervical cancer (LACC) ineligible for concurrent chemotherapy, radiotherapy (RT) alone achieves complete response rate (CRR) <70% and long-term locoregional control (LRC) <62%.
- Trial name
- HYACINCT (NCT05210270)
- Testing
- Hypofractionation
- Volunteers
- 55 people
- Sponsor
- University of Santo Tomas Hospital, Philippines
Advanced Nasopharyngeal Carcinoma
SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC
Radiotherapy and immunotherapy have achieved good survival benefit in advanced nasopharyngeal carcinoma. A number of clinical studies of immunotherapy combined with radiotherapy for nasopharyngeal carcinoma are also ongoing.
- Trial name
- NCT05652192
- Testing
- SBRT
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Zhejiang Cancer Hospital
Pancreas Cancer, Pancreas Neoplasm
Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer
This study aims to assess overall survival, quality of life and resection rates in locally advanced pancreatic cancer
- Conditions
- Pancreas Cancer, Pancreas Neoplasm, Pancreas Disease, Pancreas Adenocarcinoma
- Trial name
- SQUARE (NCT05356039)
- Where
- Sweden
- Volunteers
- 300 people
- Sponsor
- Umeå University
Advanced Hepatocellular Carcinoma
Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma
Hepatocellular carcinoma is a highly heterogeneous disease. Treatment strategies for advanced hepatocellular carcinoma are limited.
- Trial name
- NCT05620706
- Testing
- GPC3 CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen University General Hospital
Advanced Pancreatic Carcinoma, Advanced Gastric Carcinoma
Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
The efficacy of advanced pancreatic cancer and gastric cancer needs to be further improved. Claudin is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in…
- Trial name
- NCT05620732
- Testing
- Claudin18.2 CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen University General Hospital
Advanced Rectal Cancer, Liver Metastasis
A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis
Although patients with locally advanced rectal cancer and resectable liver/pulmonary metastasis could benefit from surgery resection, these patients still have a poorer prognosis compared to those without distal metastasis.
- Conditions
- Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis, Microsatellite Stable Colorectal Carcinoma
- Trial name
- Miracle-1 (NCT05359393)
- Testing
- a combination therapy including tislelizumab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Locally Advanced Gastric Cancer
Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
To evaluate the clinical efficacy of albumin paclitaxel combined with carelizumab and FLOT in the neoadjuvant treatment of locally advanced gastric cancer with different immune types
- Trial name
- NCT05610332
- Testing
- Camrelizumab, Albumin Taxol, FLOT scheme
- Where
- 2 sites in China
- Volunteers
- 216 people
- Sponsor
- Fujian Medical University
Locally Advanced, Squamous Cell Carcinoma of the Vulva
Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize)
Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes invalidating and chronic postoperative morbidity, especially in patients with high stage disease.
- Trial name
- VULCANize (NCT04192253)
- Testing
- Paclitaxel and Carboplatin
- Where
- Netherlands
- Volunteers
- 51 people
- Sponsor
- The Netherlands Cancer Institute
Advanced Solid Tumor
Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor
Prospective, single-center, single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with…
- Trial name
- NCT05539768
- Testing
- HS-IT101
- Volunteers
- 8 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Locally Advanced Non-Small Cell Lung Cancer, Metastatic NSCLC
Patient's Whole Process Follow-up Management(HOPE-1)
Our project is going to explore whether management and follow-up of locally advanced/metastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.
- Trial name
- HOPE-1 (NCT05339568)
- Testing
- Patients' whole process follow-up and management platform
- Where
- China
- Volunteers
- 1,268 people
- Sponsor
- Qianfoshan Hospital
Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer
A prospective, nationwide, implementation program of the international standard of excellence for locally advanced pancreatic cancer (LAPC) care in the Netherlands (2021[7]-2030[6]), including a multidisciplinary training program…
- Conditions
- Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Non-resectable, Chemotherapy Effect
- Trial name
- PREOPANC-4 (NCT05524090)
- Testing
- Implementation - International best-practice care
- Where
- Netherlands
- Volunteers
- 223 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Locally Advanced Gastric Cancer
Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
To evaluate the clinical efficacy of camrelizumab, apatinib Mesylate and nab-paclitaxel combined with oxplatin and S-1 in the neoadjuvant treatment of locally advanced gastric cancer with different genotypes
- Trial name
- NCT05524974
- Testing
- Camrelizumab, Oxaliplatin, S1
- Where
- China
- Volunteers
- 203 people
- Sponsor
- Fujian Medical University
Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
A phase I/II study to examine the safety, tolerability, pharmacokinetics and efficacy of XZP-5955 tablets in patients with advanced solid tumors harboring NTRK or ROS1 gene fusion
- Trial name
- NCT04996121
- Testing
- XZP-5955 tablets
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Relapsed or Advanced Non-small Cell Lung Cancer
Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer
To evaluate the tolerability, safety, pharmacokinetic characteristics and immunogenicity of Almonertinib combined with SHR-1701 in relapsed or advanced NSCLC To evaluate the efficacy of Almonertinib combined with SHR-1701 in the…
- Trial name
- NCT05503888
- Testing
- Almonertinib combined with SHR-1701, Almonertinib
- Volunteers
- 160 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Neoadjuvant Therapy, High Risk Prostate Cancer
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to evaluate the efficacy and safety of neoadjuvant intense endocrine therapy for high-risk or locally advanced prostate cancer.
- Conditions
- Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer, Intense Endocrine Therapy
- Trial name
- NCT05406999
- Testing
- ADT, Abiraterone Acetate, Prednisolone tablets
- Where
- China
- Volunteers
- 900 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Locally Advanced Nasopharyngeal Carcinoma, Envafolimab
Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.
Patients diagnosed with locally advanced nasopharyngeal carcinoma will be recruited in this study. All the patients will get 3 cycles of GP+ Envafolimab for the induction chemotherapy.
- Conditions
- Locally Advanced Nasopharyngeal Carcinoma, Envafolimab, Induction Chemotherapy, PD-L1
- Trial name
- NCT05397769
- Testing
- Envafolimab Plus Chemoradiotherapy
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Rectal Cancer
SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
This study will evaluate the efficacy and safety of SHR-1701 combined with radiotherapy and chemotherapy as perioperative treatment for locally advanced rectal cancer.
- Trial name
- NCT05300269
- Testing
- SHR-1701；Capecitabine；Oxaliplatin
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Cancer, Advanced Solid Tumor
A Study in Patients With Advanced Cancers
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
- Trial name
- NCT05320588
- Testing
- BIO-106, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 332 people
- Sponsor
- BiOneCure Therapeutics Inc.
Advanced Breast Cancer
The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
This is a multicenter, single-arm, open-label, Simon's two-stage exploratory clinical trial. 18 eligible patients with advanced breast cancer with visceral crisis will enroll in stage I.
- Trial name
- NCT05431504
- Testing
- Dalpiciclib in combination with endocrine therapy by Physicians choice
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Colorectal Cancer
Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer
This study is a single-arm, prospective, open-label observational clinical study to evaluate the efficacy and safety of Bevacizumab combined with Oxaliplatin and TAS-102 in patients with advanced unresectable rectal cancer.
- Trial name
- NCT05364489
- Testing
- Bevacizumab combined with Oxaliplatin and TAS-102
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University